health
In the battle against drug-resistant infections, a potential breakthrough has emerged.
The Global Antibiotic Research and Development Partnership (GARDP), a non-profit organisation, has successfully conducted a phase-three trial for a new antibiotic, “zoliflodacin“, which is aimed at treating gonorrhoea.
This sexually transmitted infection (STI) affects millions of people worldwide and they have become increasingly resistant to existing treatments.
Gonorrhoea is one of the most common STIs, infecting an alarming number of people each year. Africa, in particular, bears
